B001-5) for 24 hrs was stained with Human IL-27/IL-35 EBI3 Subunit Monoclonal Antibody (Catalog # MAB6456, filled histogram) or isotype control antibody (Catalog #
MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')
2Secondary Antibody (Catalog #
F0102B). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." class="big_lightbox">

B001-5) for 24 hrs was stained with Human IL-27/IL-35 EBI3 Subunit Monoclonal Antibody (Catalog # MAB6456, filled histogram) or isotype control antibody (Catalog #
MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')
2Secondary Antibody (Catalog #
F0102B). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." alt="KG-1 human acute myelogenous leukemia cell line treated with 40 ng/mL Recombinant Human IL-18/IL-1F4 (Catalog #
B001-5) for 24 hrs was stained with Human IL-27/IL-35 EBI3 Subunit Monoclonal Antibody (Catalog # MAB6456, filled histogram) or isotype control antibody (Catalog #
MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')
2Secondary Antibody (Catalog #
F0102B). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." class="big_thumb" />